{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:17:05Z","timestamp":1794622625484,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA175386"],"award-info":[{"award-number":["R01 CA175386"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA108961"],"award-info":[{"award-number":["R01 CA108961"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity also drives generation of neoepitopes, which prime anti-tumor T cells. Here, we show that overexpression of APOBEC3B in tumors increases resistance to chemotherapy, but simultaneously heightens sensitivity to immune checkpoint blockade in a murine model of melanoma. However, in the vaccine setting, APOBEC3B-mediated mutations reproducibly generate heteroclitic neoepitopes in vaccine cells which activate de novo T cell responses. These cross react against parental, unmodified tumors and lead to a high rate of cures in both subcutaneous and intra-cranial tumor models. Heteroclitic Epitope Activated Therapy (HEAT) dispenses with the need to identify patient specific neoepitopes and tumor reactive T cells ex vivo. Thus, actively driving a high mutational load in tumor cell vaccines increases their immunogenicity to drive anti-tumor therapy in combination with immune checkpoint blockade.<\/jats:p>","DOI":"10.1038\/s41467-020-14568-7","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T06:04:14Z","timestamp":1581055454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Christopher B.","family":"Driscoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8399-1537","authenticated-orcid":false,"given":"Matthew R.","family":"Schuelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phonphimon","family":"Wongthida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Tonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Molan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Wetmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardev","family":"Pandha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose S.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-9112","authenticated-orcid":false,"given":"Reuben","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Evgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Vile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"14568_CR1","doi-asserted-by":"crossref","unstructured":"Annovazzi, L., Mellai, M. & Schiffer, D. Chemotherapeutic drugs: DNA damage and repair in glioblastoma. Cancers 9, 57 (2017).","DOI":"10.3390\/cancers9060057"},{"key":"14568_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/bjc.2017.376","volume":"118","author":"JS Brown","year":"2018","unstructured":"Brown, J. S., Sundar, R. & Lopez, J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br. J. Cancer 118, 312\u2013324 (2018).","journal-title":"Br. J. Cancer"},{"key":"14568_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366\u2013370 (2013).","journal-title":"Nature"},{"key":"14568_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12910","volume":"7","author":"M Smid","year":"2016","unstructured":"Smid, M. et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat. Commun. 7, 12910 (2016).","journal-title":"Nat. Commun."},{"key":"14568_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semcancer.2017.11.003","volume":"52","author":"D Hammerl","year":"2018","unstructured":"Hammerl, D. et al. Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin. Cancer Biol. 52, 178\u2013188 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"14568_CR6","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.18632\/oncotarget.23344","volume":"9","author":"AP Glaser","year":"2018","unstructured":"Glaser, A. P. et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 9, 4537\u20134548 (2018).","journal-title":"Oncotarget"},{"key":"14568_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/ng.2701","volume":"45","author":"MB Burns","year":"2013","unstructured":"Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977\u2013983 (2013).","journal-title":"Nat. Genet."},{"key":"14568_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.tibs.2016.05.001","volume":"41","author":"JD Salter","year":"2016","unstructured":"Salter, J. D., Bennett, R. P. & Smith, H. C. The APOBEC protein family: united by structure, divergent in function. Trends Biochem. Sci. 41, 578\u2013594 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"14568_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704\u2013712 (2015).","journal-title":"Cancer Discov."},{"key":"14568_CR10","doi-asserted-by":"publisher","first-page":"e1601737","DOI":"10.1126\/sciadv.1601737","volume":"2","author":"EK Law","year":"2016","unstructured":"Law, E. K. et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci. Adv. 2, e1601737 (2016).","journal-title":"Sci. Adv."},{"key":"14568_CR11","doi-asserted-by":"publisher","first-page":"e1284719","DOI":"10.1080\/2162402X.2017.1284719","volume":"6","author":"A Boichard","year":"2017","unstructured":"Boichard, A., Tsigelny, I. F. & Kurzrock, R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology 6, e1284719 (2017).","journal-title":"Oncoimmunology"},{"key":"14568_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13578-017-0156-4","volume":"7","author":"J Zou","year":"2017","unstructured":"Zou, J., Wang, C., Ma, X., Wang, E. & Peng, G. APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci. 7, 29 (2017).","journal-title":"Cell Biosci."},{"key":"14568_CR13","doi-asserted-by":"crossref","unstructured":"Jarvis M. C., Ebrahimi D., Temiz N. A., Harris R. S. Mutation signatures including APOBEC in cancer cell lines. JNCI Cancer Spectr 2, pky002\u00a0(2018).","DOI":"10.1093\/jncics\/pky002"},{"key":"14568_CR14","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","volume":"37","author":"S Wang","year":"2018","unstructured":"Wang, S., Jia, M., He, Z. & Liu, X. S. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene 37, 3924\u20133936 (2018).","journal-title":"Oncogene"},{"key":"14568_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2326-6066.CIR-18-0013","volume":"7","author":"L Evgin","year":"2019","unstructured":"Evgin, L. et al. Sub-optimal T cell therapy crives a tumor cell mutator phenotype that promotes escape from frontline treatment. Cancer Immunol. Res. 7, 828\u2013840 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"14568_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2018.08.003","volume":"11","author":"AL Huff","year":"2018","unstructured":"Huff, A. L. et al. APOBEC3 mediates resistance to oncolytic viral therapy. Mol. Ther. Oncolytics 11, 1\u201313 (2018).","journal-title":"Mol. Ther. Oncolytics"},{"key":"14568_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.chembiol.2017.10.007","volume":"25","author":"ME Olson","year":"2018","unstructured":"Olson, M. E., Harris, R. S. & Harki, D. A. APOBEC enzymes as targets for virus and cancer therapy. Cell Chem. Biol. 25, 36\u201349 (2018).","journal-title":"Cell Chem. Biol."},{"key":"14568_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"14568_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"14568_CR20","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"14568_CR21","doi-asserted-by":"publisher","first-page":"xii3","DOI":"10.1093\/annonc\/mdx544","volume":"28","author":"SK Saini","year":"2017","unstructured":"Saini, S. K., Rekers, N. & Hadrup, S. R. Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. Ann. Oncol. 28, xii3\u2013xii10 (2017).","journal-title":"Ann. Oncol."},{"key":"14568_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00002371-200501000-00007","volume":"28","author":"J Zhou","year":"2005","unstructured":"Zhou, J., Dudley, M. E., Rosenberg, S. A. & Robbins, P. F. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28, 53\u201362 (2005).","journal-title":"J. Immunother."},{"key":"14568_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Johnson, B. A. 3rd, Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209\u2013222 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"14568_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116\u2013120 (2017).","journal-title":"Nature"},{"key":"14568_CR25","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","volume":"9","author":"MH Geukes Foppen","year":"2015","unstructured":"Geukes Foppen, M. H., Donia, M., Svane, I. M. & Haanen, J. B. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol. Oncol. 9, 1918\u20131935 (2015).","journal-title":"Mol. Oncol."},{"key":"14568_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/annonc\/mdy003","volume":"29","author":"S Venkatesan","year":"2018","unstructured":"Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563\u2013572 (2018).","journal-title":"Ann. Oncol."},{"key":"14568_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1084\/jem.188.2.277","volume":"188","author":"WW Overwijk","year":"1998","unstructured":"Overwijk, W. W. et al. gp100\/pmel 17 is a murine tumor rejection antigen: induction of \u201cself\u201d-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277\u2013286 (1998).","journal-title":"J. Exp. Med."},{"key":"14568_CR28","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/sj.mt.6300290","volume":"15","author":"JD Wolchok","year":"2007","unstructured":"Wolchok, J. D. et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther. 15, 2044\u20132050 (2007).","journal-title":"Mol. Ther."},{"key":"14568_CR29","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1084\/jem.188.9.1553","volume":"188","author":"R Dyall","year":"1998","unstructured":"Dyall, R. et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188, 1553\u20131561 (1998).","journal-title":"J. Exp. Med."},{"key":"14568_CR30","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.4049\/jimmunol.170.10.5188","volume":"170","author":"JS Gold","year":"2003","unstructured":"Gold, J. S. et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 170, 5188\u20135194 (2003).","journal-title":"J. Immunol."},{"key":"14568_CR31","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/0008-5472.CAN-12-0600","volume":"72","author":"DM Rommelfanger","year":"2012","unstructured":"Rommelfanger, D. M. et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res. 72, 4753\u20134764 (2012).","journal-title":"Cancer Res."},{"key":"14568_CR32","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/hum.2010.216","volume":"22","author":"P Wongthida","year":"2011","unstructured":"Wongthida, P. et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther. 22, 1343\u20131353 (2011).","journal-title":"Hum. Gene Ther."},{"key":"14568_CR33","doi-asserted-by":"publisher","first-page":"8538","DOI":"10.1128\/JVI.02645-10","volume":"85","author":"V Pak","year":"2011","unstructured":"Pak, V., Heidecker, G., Pathak, V. K. & Derse, D. The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J. Virol. 85, 8538\u20138547 (2011).","journal-title":"J. Virol."},{"key":"14568_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<267::AID-IJC23>3.0.CO;2-D","volume":"71","author":"RG Vile","year":"1997","unstructured":"Vile, R. G. et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71, 267\u2013274 (1997).","journal-title":"Int. J. Cancer"},{"key":"14568_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/ng.3378","volume":"47","author":"K Chan","year":"2015","unstructured":"Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067\u20131072 (2015).","journal-title":"Nat. Genet."},{"key":"14568_CR36","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.4049\/jimmunol.1302101","volume":"191","author":"S Paul","year":"2013","unstructured":"Paul, S. et al. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J. Immunol. 191, 5831\u20135839 (2013).","journal-title":"J. Immunol."},{"key":"14568_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","volume":"2","author":"EF Fritsch","year":"2014","unstructured":"Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522\u2013529 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"14568_CR38","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.4049\/jimmunol.166.9.5366","volume":"166","author":"MP Velders","year":"2001","unstructured":"Velders, M. P. et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166, 5366\u20135373 (2001).","journal-title":"J. Immunol."},{"key":"14568_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0263-6","volume":"8","author":"B Schubert","year":"2016","unstructured":"Schubert, B. & Kohlbacher, O. Designing string-of-beads vaccines with optimal spacers. Genome Med. 8, 9 (2016).","journal-title":"Genome Med."},{"key":"14568_CR40","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"14568_CR41","doi-asserted-by":"publisher","first-page":"11746","DOI":"10.18632\/oncotarget.7459","volume":"7","author":"R Friedman","year":"2016","unstructured":"Friedman, R. Drug resistance in cancer: molecular evolution and compensatory proliferation. Oncotarget 7, 11746\u201311755 (2016).","journal-title":"Oncotarget"},{"key":"14568_CR42","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.ymthe.2017.01.023","volume":"25","author":"KG Shim","year":"2017","unstructured":"Shim, K. G. et al. Inhibitory receptors induced by VSV viroimmunotherapy are not necessarily targets for improving treatment efficacy. Mol. Ther. 25, 962\u2013975 (2017).","journal-title":"Mol. Ther."},{"key":"14568_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","volume":"38","author":"KC Soares","year":"2015","unstructured":"Soares, K. C. et al. PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother. 38, 1\u201311 (2015).","journal-title":"J. Immunother."},{"key":"14568_CR44","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1172\/JCI93303","volume":"128","author":"Y Hailemichael","year":"2018","unstructured":"Hailemichael, Y. et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J. Clin. Invest. 128, 1338\u20131354 (2018).","journal-title":"J. Clin. Invest."},{"key":"14568_CR45","doi-asserted-by":"publisher","first-page":"e1002497","DOI":"10.1371\/journal.pmed.1002497","volume":"15","author":"P Srinivasan","year":"2018","unstructured":"Srinivasan, P., Wu, X., Basu, M., Rossi, C. & Sandler, A. D. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: a mouse neuroblastoma model that mimics human disease. PLoS Med. 15, e1002497 (2018).","journal-title":"PLoS Med."},{"key":"14568_CR46","first-page":"201","volume":"12","author":"J Kleponis","year":"2015","unstructured":"Kleponis, J., Skelton, R. & Zheng, L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol. Med. 12, 201\u2013208 (2015).","journal-title":"Cancer Biol. Med."},{"key":"14568_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/acschemneuro.5b00336","volume":"7","author":"AC Solomos","year":"2016","unstructured":"Solomos, A. C. & Rall, G. F. Get it through your thick head: emerging principles in neuroimmunology and neurovirology redefine central nervous system \u201cImmune Privilege\u201d. ACS Chem. Neurosci. 7, 435\u2013441 (2016).","journal-title":"ACS Chem. Neurosci."},{"key":"14568_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nri.2017.152","volume":"18","author":"J Kipnis","year":"2018","unstructured":"Kipnis, J. & Filiano, A. J. Neuroimmunology in 2017: the central nervous system: privileged by immune connections. Nat. Rev. Immunol. 18, 83\u201384 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"14568_CR49","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459\u20131468 (2018).","journal-title":"Nat. Med."},{"key":"14568_CR50","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart, D. et al. Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking. Proc. Natl Acad. Sci. USA 115, E1540\u2013E1549 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14568_CR51","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979\u2013993 (2012).","journal-title":"Cell"},{"key":"14568_CR52","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970\u2013976 (2013).","journal-title":"Nat. Genet."},{"key":"14568_CR53","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.celrep.2014.05.012","volume":"7","author":"S Henderson","year":"2014","unstructured":"Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7, 1833\u20131841 (2014).","journal-title":"Cell Rep."},{"key":"14568_CR54","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109\u20132121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"14568_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"14568_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12918","volume":"7","author":"GJ Starrett","year":"2016","unstructured":"Starrett, G. J. et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat. Commun. 7, 12918 (2016).","journal-title":"Nat. Commun."},{"key":"14568_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"14568_CR58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/bies.200900122","volume":"32","author":"M Mihailovich","year":"2010","unstructured":"Mihailovich, M., Militti, C., Gabaldon, T. & Gebauer, F. Eukaryotic cold shock domain proteins: highly versatile regulators of gene expression. BioEssays 32, 109\u2013118 (2010).","journal-title":"BioEssays"},{"key":"14568_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.virusres.2018.03.006","volume":"249","author":"M Muto","year":"2018","unstructured":"Muto, M. et al. Identification and analysis of host proteins that interact with the 3\u2019-untranslated region of tick-borne encephalitis virus genomic RNA. Virus Res. 249, 52\u201356 (2018).","journal-title":"Virus Res."},{"key":"14568_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01744-5","volume":"8","author":"H Ju Lee","year":"2017","unstructured":"Ju Lee, H. et al. A post-transcriptional program coordinated by CSDE1 prevents intrinsic neural differentiation of human embryonic stem cells. Nat. Commun. 8, 1456 (2017).","journal-title":"Nat. Commun."},{"key":"14568_CR61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1755-148X.2008.00442.x","volume":"21","author":"F Rambow","year":"2008","unstructured":"Rambow, F. et al. Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLiM swine model. Pigment Cell Melanoma Res. 21, 147\u2013161 (2008).","journal-title":"Pigment Cell Melanoma Res."},{"key":"14568_CR62","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccell.2016.10.004","volume":"30","author":"L Wurth","year":"2016","unstructured":"Wurth, L. et al. UNR\/CSDE1 drives a post-transcriptional program to promote melanoma invasion and metastasis. Cancer Cell 30, 694\u2013707 (2016).","journal-title":"Cancer Cell"},{"key":"14568_CR63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nbt.2157","volume":"30","author":"J Pulido","year":"2012","unstructured":"Pulido, J. et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat. Biotechnol. 30, 337\u2013343 (2012).","journal-title":"Nat. Biotechnol."},{"key":"14568_CR64","first-page":"4096","volume":"56","author":"JR Gingrich","year":"1996","unstructured":"Gingrich, J. R. et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56, 4096\u20134102 (1996).","journal-title":"Cancer Res."},{"key":"14568_CR65","first-page":"3325","volume":"57","author":"BA Foster","year":"1997","unstructured":"Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. & Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325\u20133330 (1997).","journal-title":"Cancer Res."},{"key":"14568_CR66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1750-3639.2010.00468.x","volume":"21","author":"V Caretti","year":"2011","unstructured":"Caretti, V. et al. Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model. Brain Pathol. 21, 441\u2013451 (2011).","journal-title":"Brain Pathol."},{"key":"14568_CR67","doi-asserted-by":"crossref","unstructured":"Nair S., Rein A. In vitro assay for cytidine deaminase activity of APOBEC3 protein. Bio Protoc. 4, e1266 (2014).","DOI":"10.21769\/BioProtoc.1266"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14568-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14568-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14568-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T13:12:03Z","timestamp":1670245923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14568-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14568"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-14568-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G.V., L.E., T.K. and A.L.H. have submitted a patent pertaining to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"790"}}